-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTERN PHARMA ANNOUNCES PEER-REVIEWED PUBLICATION OF PHASE 1A LP-184 DATA IN RECURRENT GLIOBLASTOMA, SUPPORTING A PHASE 1B/2A COMBINATION TRIAL WITH SPIRONOLACTONE

Reuters·11/10/2026 13:45:00

Please log in to view news